USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Emerging Landscape of Targeted Protein Degradation Therapeutics
Rapid Technology Advances Bolster a Robust Therapeutic Pipeline
29-Jun-2023
Global
Technology Research
DAA6-01-00-00-00
HC03684-GL-TR_27822
$4,950.00
Special Price $3,712.50 save 25 %
This Frost & Sullivan research report provides an in-depth analysis of the emerging targeted protein degradation (TPD) space. TPD strategies enable treating various diseases not yet treatable via conventional approaches by attacking disease-causing proteins in a controlled manner, thus reducing the risk of side effects.
It is estimated that 80% of a cell’s proteome cannot be targeted via traditional approaches such as small molecule inhibitors, ASO, or monoclonal antibodies, which has led to the development of TPD approaches. Indeed, TPD has advanced enormously in the last two decades, and PROTACs have emerged as the most common protein degrader researched until now. As new technologies emerge, several types of protein degraders have been developed.
Two main types exist: intracellular and extracellular degraders. Until now, intracellular protein degraders have been the most extensively studied. These degrade intracellular proteins by leveraging the ubiquitin-proteasomal degradation pathway, but an estimated 40% of genes encoding extracellular and membrane-associated proteins cannot be targeted by intracellular protein degraders, leading to the development of extracellular protein degradation.
Increased private and public funding is an important factor driving the growth of targeted protein degradation technology. This report includes an analysis of funding trends in the TPD space.
This report discusses the different types of extracellular and intracellular protein degraders and R&D focus areas; it analyses the applicability of different degraders across various diseases and identifies their clinical translation and related key players. Finally, Frost & Sullivan has identified four growth opportunities for TPD that could potentially transform the market.
Questions that this report seeks to answer include:
1. What are the key drivers or challenges for TPD development?
2. How do the private funding and partnership landscapes look for TPD?
3. Who are the key industry participants developing targeted protein degraders?
4. What are the R&D trends emerging across TPD that could further shape the development of protein degraders?
Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Targeted Protein Degradation Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
Introduction
Growth Drivers
Growth Driver Analysis
Growth Driver Analysis (continued)
Growth Restraints
Growth Restraints Analysis
Scope of Analysis
Segmentation
The Need for Targeted Protein Degraders
TPD—Evolution and Clinical aspect
Intracellular Targeted Protein Degraders in Clinical Development
Intracellular Targeted Protein Degraders—PROTACs
Emerging Intracellular Targeted Protein Degraders
Emerging Intracellular Targeted Protein Degraders (continued)
Innovation Spotlight—Intracellular Protein Degradation
Development of Extracellular Protein Degradation Therapeutics
Challenges for Extracellular Protein Degrader Development
Extracellular Protein Degradation Approaches
Emerging Classes of Extracellular Protein Degraders
Emerging Classes of Extracellular Protein Degraders (continued)
Innovation Spotlight—Extracellular Protein Degradation
Key Differences Between Extracellular and Intracellular Protein Targeting
Targeted Protein Degradation Technology Snapshot
Targeted Protein Degradation Technology Snapshot (continued)
R&D Innovation Trends
R&D Innovation Trends (continued)
Protein Degraders in Healthcare and Beyond
Protein Degraders across Different Disease Areas
Protein Degraders across Different Disease Areas (continued)
Key Players and Therapeutics Areas of Focus
Key Players and Therapeutics Areas of Focus (continued)
Protein Degraders Innovation Landscape
Public and Private Funding for TPD Therapy Development
Public and Private Funding for TPD Therapy Development (continued)
Public and Private Funding for TPD Therapy Development (continued)
Partnership Landscape of Biopharma Companies in TPD Therapeutics Development
Partnership Landscape of Biopharma Companies in TPD Therapeutics Development (continued)
Partnership Landscape of Biopharma Companies in TPD Therapeutics Development (continued)
TPD Companies’ Partnerships for Developing TPD Therapeutics
Growth Opportunity 1: Efficient and Tissue-specific Degrader Delivery
Growth Opportunity 1: Efficient and Tissue-specific Degrader Delivery (continued)
Growth Opportunity 2: Novel E3 Ligases Discovery and Design
Growth Opportunity 2: Novel E3 Ligases Discovery and Design (continued)
Growth Opportunity 3: Advanced PROTACs Development
Growth Opportunity 3: Advanced PROTACs Development (continued)
Growth Opportunity 4: Research and Product Development Partnerships to Develop Next-gen TPD Therapeutics
Growth Opportunity 4: Research and Product Development Partnerships to Develop Next-gen TPD Therapeutics (continued)
Appendix
Appendix
Your Next Steps
Why Frost, Why Now?
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Recent related Healthcare research
06 Aug 2026 | Global | Technology Research
Decentralized Clinical Trials Powered by Blockchain and Digital Twins
This report examines how decentralized clinical trials (DCTs), enabled by blockchain, digital twins, and artificial intelligence, are reshaping global clinical research. It traces the shift from site-centric to patient-centric models and quantifies the growing scale, globalization, and complexity of...
04 Aug 2026 | Global | Market Research
Global Capnography Devices Market, Forecast to 2031
The capnography market is undergoing a significant transformation from its traditional role in anesthesia and intensive care monitoring to a broader, continuous respiratory surveillance ecosystem. This evolution is being driven by increasing integration of capnography into multiparameter monitoring ...
31 Jul 2026 | Global | Market Research
Growth Opportunities in Small-Molecule Contract Development and Manufacturing Organizations, Global, 2026–2031
The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward s...
30 Jul 2026 | Global | Technology Research
Innovations and Growth Opportunities in Advanced Medical Devices, Artificial Intelligence Solutions, Wearables and Drug Delivery Solutions
The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, artificial intelligence solutions, wearables and drug delivery solutions.
The issue features advanced medical devices such as non-invasive bimoda...
30 Jul 2026 | Global | Frost Radar
Frost Radar™: Life Sciences Regulatory Information Management Platforms, 2026
The regulatory technology market in life sciences has, over the last five years, quietly transformed from a back-office category dominated by document repositories and submission publishing tools to one of the most consequential software segments serving the pharmaceutical, biotech, and medical devi...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Technology Research |
|---|---|
| Author | Priyanka Jain |
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Podcast | No |
| WIP Number | DAA6-01-00-00-00 |